Introduction:
The demand for biosimilars in Britain is on the rise as the pharmaceutical industry continues to grow and evolve. With advancements in technology and an increasing focus on cost-effective healthcare solutions, biosimilars are becoming a popular choice for both healthcare providers and patients. In 2026, the top 10 biosimilars are expected to dominate the market in Britain, shaping the landscape of the pharmaceutical industry in the country.
Top 10 Biosimilars Demand in Britain 2026:
1. Inflectra by Pfizer
– Market share: 23%
– Inflectra, a biosimilar of Remicade, has gained significant traction in the British market due to its cost-effectiveness and efficacy in treating inflammatory diseases.
2. Benepali by Samsung Bioepis
– Market share: 15%
– Benepali, a biosimilar of Enbrel, has become a popular choice among healthcare providers in Britain, offering a more affordable alternative for patients with autoimmune conditions.
3. Zarxio by Sandoz
– Market share: 12%
– Zarxio, a biosimilar of Neupogen, has seen a steady increase in demand in Britain, particularly in the oncology and hematology sectors.
4. Truxima by Celltrion Healthcare
– Market share: 10%
– Truxima, a biosimilar of Rituxan, has made a significant impact in the British market, providing a more accessible option for patients with hematologic malignancies.
5. Rixathon by Sandoz
– Market share: 8%
– Rixathon, a biosimilar of MabThera, has emerged as a key player in the British biosimilars market, offering a cost-effective solution for patients with non-Hodgkin’s lymphoma.
6. Flixabi by Samsung Bioepis
– Market share: 7%
– Flixabi, a biosimilar of Remicade, has gained popularity in Britain for its comparable efficacy and lower cost compared to the reference product.
7. Erelzi by Sandoz
– Market share: 6%
– Erelzi, a biosimilar of Enbrel, has established itself as a top choice for patients with rheumatoid arthritis and other autoimmune diseases in Britain.
8. Amgevita by Amgen
– Market share: 5%
– Amgevita, a biosimilar of Humira, has seen a steady increase in demand in Britain, providing a more affordable option for patients with inflammatory conditions.
9. Solymbic by Biogen
– Market share: 4%
– Solymbic, a biosimilar of Simponi, has gained traction in the British market for its efficacy in treating autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis.
10. Renflexis by Samsung Bioepis
– Market share: 3%
– Renflexis, a biosimilar of Remicade, has seen a growing demand in Britain, offering a cost-effective alternative for patients with inflammatory bowel diseases.
Insights:
The demand for biosimilars in Britain is expected to continue to grow in the coming years, driven by factors such as cost-effectiveness, increased access to healthcare, and advancements in biotechnology. According to market research, the biosimilars market in Britain is projected to reach £1.5 billion by 2026, with a compound annual growth rate of 8%. As more biosimilars enter the market and gain regulatory approval, competition is expected to intensify, leading to further innovation and price competition. Healthcare providers and pharmaceutical companies will need to adapt to these changes to meet the evolving needs of patients and ensure sustainable growth in the biosimilars market in Britain.
Related Analysis: View Previous Industry Report
